Background: Eslicarbazepine acetate (ESL) is a new anti-epileptic drug (AED) chemically
related to oxcarbazepine (OXC) and carbamazepine (CBZ) and is increasingly used in …

Eslicarbazepine acetate (ESL) is a new antiepileptic drug whose mechanism of action is
blockade of the voltage-gated sodium channel (VGSC). However, in respect to …

Purpose Investigate the pharmacokinetics of once‐daily (QD; 900 mg) and twice‐daily (BID;
450 mg) regimens of eslicarbazepine acetate (ESL) and BID (450 mg) regimen of …

Eslicarbazepine acetate (ESL) is a prodrug antiseizure medication for the treatment of focal
seizures. ESL shows a well‐established pharmacokinetic (PK)‐pharmacodynamic …

Objective Eslicarbazepine acetate (ESL) is a once‐daily oral antiseizure medication. Its
safety and tolerability from clinical trials have been mostly confirmed by real‐world data. The …

Epilepsy is a common neurological disorder. Despite a broad range of commonly used
antiepileptic drugs, approximately 30% of patients with epilepsy have drug resistance or …

Purpose: To evaluate the pharmacokinetics and tolerability of once‐daily eslicarbazepine
acetate (ESL) and twice‐daily oxcarbazepine (OXC) and their metabolites in cerebrospinal …

Purpose Eslicarbazepine acetate (ESL) is a new generation voltage-gated sodium channel
blocker. It has completed one phase II clinical trial and three phase III clinical trials, two of …

Introduction: Up to 30% of the patients diagnosed with epilepsy will continue suffering from
seizures despite treatment with antiepileptic drugs, either in monotherapy or polytherapy …

Purpose: To investigate the bioequivalence of the final tablet formulation of eslicarbazepine
acetate (ESL) and the tablet formulation used in pivotal clinical studies. Methods: Single …